Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. The company's President and CEO, Michael Egholm, PhD, will present at a fireside chat on Friday, September 6, 2024, at 8:30 a.m. ET.
The presentation will be webcast live on the company's Investor Relations page under Events & Presentations. A recording of the webcast will also be archived and available for later viewing at investors.standardbio.com. This conference, running from September 4th to 6th, provides Standard BioTools with an opportunity to showcase its developments and engage with industry professionals and investors.
Details
News Market Reaction – LAB
The recorded move for LAB in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm’s fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.